Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Intravenous high-dose methotrexate (MTX ≥ 1 g/m 2 ) is frequently used in patients with cerebral lymphoma or other malignancies. In addition to its potent efficacy, it is known to have pronounced toxicity and life-threatening side effects. Regular-level monitoring at short and defined intervals is mandatory. This study aimed to evaluate the possibility of replacing peripheral blood sampling with blood samples from central venous catheters for therapeutic monitoring of MTX in adults.

Methods: A total of 6 patients and 7 cycles of chemotherapy (6 females; 5 with cerebral non-Hodgkin lymphoma and 1 with osteosarcoma, median age 51 years; range 33-62 years) were included. An immunoassay was used for quantitative analysis of MTX levels. The measurement points were obtained in the time intervals of 24, 42, 48, and 72 hours, and afterward, every 24 hours until the level was below <0.1 µmol/L. After flushing with 10 mL of saline solution and discarding 10 mL of venous blood, blood was drawn from the central venous access through which MTX had previously been administered. Simultaneously, MTX levels were obtained from peripheral venipuncture.

Results: Methotrexate levels from central venous access and MTX levels from peripheral venipuncture showed a significant correlation (r = 0.998; P < 0.01; n = 35). During withdrawal from the central access group, 17 values showed a lower MTX level, 10 showed a higher level, and 8 showed no difference. However, the MTX level difference was not significant ( P = 0.997, linear mixed model). No increase in the dose of calcium folinate was necessary based on the collected MTX levels.

Conclusions: In adults, MTX monitoring from central venous access is not inferior to monitoring from peripheral venipuncture. Repeated venipuncture to measure MTX levels can be replaced after establishing standardized instructions for proper sampling by a central venous catheter.

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000001080DOI Listing

Publication Analysis

Top Keywords

central venous
8
methotrexate drug
4
drug monitoring
4
monitoring central
4
central access
4
access blood
4
blood sample
4
sample collection
4
collection central
4
venous access
4

Similar Publications

Effect of ECMO Flow Variations on Pulmonary Capillary Wedge Pressure in Patients With Cardiogenic Shock.

J Am Coll Cardiol

September 2025

Service de Médecine Intensive-Réanimation, Institut de Cardiologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.

Background: The hemodynamic effects of femoro-femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO) on pulmonary capillary wedge pressure (PCWP) remain poorly defined. High ECMO flow is believed to increase PCWP and the risk of pulmonary edema; yet, supporting in vivo physiological data are lacking.

Objectives: The purpose of this study was to evaluate the impact of incremental femoro-femoral VA-ECMO flow variations on PCWP, hemodynamic, and echocardiographic parameters in patients with cardiogenic shock during the early phase of VA-ECMO support, after stabilization.

View Article and Find Full Text PDF

Background: Previous trials have demonstrated increased 5-year risks for adverse clinical events after coronary artery implantation of poly-l-lactic acid-based bioresorbable scaffolds (BRS) compared with cobalt chromium (CoCr) everolimus-eluting stents (EES).

Objectives: The aim of this study was to evaluate the 5-year clinical outcomes of the novel sirolimus-eluting NeoVas BRS compared with CoCr EES.

Methods: A total of 560 patients with single de novo native coronary artery lesions with reference vessel diameter 2.

View Article and Find Full Text PDF

Background: The risk-benefit balance of extended anticoagulation in patients with metastatic cancer remains unclear.

Objectives: This prespecified subgroup analysis aimed to evaluate the efficacy and safety of 12-and 3-month edoxaban treatment in patients with cancer-associated isolated distal deep vein thrombosis (DVT) based on cancer metastasis.

Methods: The ONCO DVT study, a randomized clinical trial, included 601 patients with cancer-associated isolated distal DVT, divided into metastasis (N = 147) and no metastasis subgroups (N = 454).

View Article and Find Full Text PDF

Objective: To investigate the clinical efficacy and safety of intravenous omadacycline compared to intravenous tigecycline in patients with severe pneumonia caused by carbapenem-resistant gram-negative bacilli (CRGNB), and to explore the factors influencing 28-day all-cause mortality.

Methods: Our retrospective analysis was conducted on adult patients with CRGNB-associated severe pneumonia who received intravenous omadacycline or tigecycline for at least 72 hours in the intensive care unit (ICU) between April 1, 2023, and March 31, 2025. The primary outcome was 28-day all-cause mortality, while secondary endpoints included clinical efficacy and microbiological clearance rates.

View Article and Find Full Text PDF

Background: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.

Objective: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).

Methods: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed.

View Article and Find Full Text PDF